Related Experiment Video
Updated: Sep 27, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis
Erik G Lund1, John G Menke, Carl P Sparrow
1Department of Atherosclerosis, Merck Research Laboratories, PO Box 2000, Rahway, NJ 0706, USA. erik_lund@merck.com
Abstract:
The recent identification of liver X receptors (LXR) as regulators of the cholesterol and phospholipid export pump ABCA1 has raised the possibility that LXR agonists could be developed as HDL-raising agents, possibly also acting on the artery wall to stimulate cholesterol efflux from lipid-laden macrophages. Presently several pharmaceutical companies are working to develop such compounds, which will require finding a path for separating these beneficial effects from the detrimental stimulation of triglyceride synthesis also inherent to LXR agonists. Other challenges to the drug development process include species differences, which makes prediction of in vivo effects of LXR agonists in humans difficult. This review summarizes the present state of knowledge on LXR as a drug target and discusses possible solutions for dissociating the favorable effects of LXR agonists from their unwanted effects.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
